Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 623.

https://doi.org/10.1182/blood-2023-179160

Published: 2023

Journal Articles

Effect of New or Worsening Anemia on Clinical Outcomes in 2233 Patients with Myelofibrosis Treated with Ruxolitinib in the Expanded-Access Jump Study

Vikas Gupta, Paola Guglielmelli, JE Hamer-Maansson, Evan M. Braunstein, Haifa Kathrin Al-Ali

Blood (2023) 142 (Supplement 1): 5174.

https://doi.org/10.1182/blood-2023-179417

Published: 2023

Journal Articles

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study

Claire N Harrison, Ruben Mesa, Moshe Talpaz, Haifa Kathrin Al-Ali, Blanca Xicoy, Francesco Passamonti, Francesca Palandri, Giulia Benevolo, Alessandro M. Vannucchi, Clemence Mediavilla, Alessandra Iurlo, InHo Kim, Patrick Brown, Christopher Hernandez, Shelonitda Rose, Jia Wang, Jean-Jacques Kiladjian

Blood (2023) 142 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2023-173391

Published: 2023

Journal Articles

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Maria Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreño, Andrea Patriarca, Haifa Kathrin Al-Ali, Marcio Andrade, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro, Jean-Jacques Kiladjian, Estefanía Bolaños, Florian H. Heidel, Keina Quiroz, Martin Griesshammer, Valentín García Gutiérrez, Alberto Marin Sanchez, Juan Carlos Hernandez Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagüés, Rajko Kusec, Blanca Xicoy, Margarita Guenova, Begoña Navas, Anna Angona, Edyta Cichocka, Anna Masternak, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, Alessandro M. Vannucchi

Blood (2022) 140 (Supplement 1): 6815–6818.

https://doi.org/10.1182/blood-2022-158902

Published: 2022

Journal Articles

Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum

Blood (2022) 140 (Supplement 1): 6803–6805.

https://doi.org/10.1182/blood-2022-162877

Published: 2022

Journal Articles

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 2126–2129.

https://doi.org/10.1182/blood-2022-157684

Published: 2022

Journal Articles

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Blood (2022) 140 (Supplement 1): 1514–1517.

https://doi.org/10.1182/blood-2022-162783

Published: 2022

Journal Articles

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

Pankit Vachani, Andrzej Lange, Regina Garcia Delgado, Haifa Kathrin Al-Ali, Jesus Maria Hernández-Rivas, Jean-Jacques Kiladjian, Alessandro Vannucchi, Andrew Charles Perkins, Venu Valmeekam, Cecile Marie Krejsa, Anne Uyei, Jesse McGreivy, Wayne P. Rothbaum, John Mascarenhas, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2021-147543

Published: 2021

Journal Articles

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Nicola Vianelli, Giulia Benevolo, Alessandro Vannucchi, Claire N. Harrison, Michael Loschi, Haifa Kathrin Al-Ali, Massimiliano Bonifacio, Francisco Cervantes, Tomasz Wrobel, Giovanni Barosi, Jean-Jaques Kiladjian, Srdan Verstovsek, Ruben A. Mesa, Shelonitda Rose, Vishwanath Gharpure, Christopher Hernandez, Jun Zhang, Francesco Passamonti

Blood (2021) 138 (Supplement 1): 3643.

https://doi.org/10.1182/blood-2021-147614

Published: 2021

Journal Articles

The Incidence of Mastocytosis in Patients with Unclear Cytopenia and/or Leucocytosis: The Hryd Study

Hannah Seemann, Nadja Jaekel, Susann Schulze, MD, Juliane Grimm, MD, Ole Vollstaedt, MD, Anja Haak, PhD, Dietger Niederwieser, MD PhD, Claudia Wickenhauser, MD, Haifa Kathrin Al-Ali, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-139311

Published: 2020

Journal Articles

Phenotypes of JAK2 -Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study

Tony Hennersdorf, Nadja Jaekel, Susann Schulze, MD, Dietrich Kaempfe, MD, Claudia Spohn, MD, Regina Moeller, MD, Maik Schwarz, MD, Hans-Juergen Hurtz, MD, Joern Ruessel, MD, Peter Tornow, Ute Neef, MD, Marion Schmalfeld, MD, Kathleen Jentsch-Ullrich, MD, Thoralf Lange, MD, Christian Junghanss, MD, Brigitte Kragl, MD, Haifa Kathrin Al-Ali, MD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-139366

Published: 2020

Journal Articles

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Blood (2019) 134 (Supplement_1): 1358.

https://doi.org/10.1182/blood-2019-125262

Published: 2019

Journal Articles

Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)

Nadja Jaekel, Susann Schulze, MD, Udo Siebolts, MD, Anja Haak, PhD, Nikolaos Pazaitis, MD, Michael Cross, PhD, Dietger Niederwieser, MD, Mathias Hänel, MD, Georg Maschmeyer, MD, Maxi Wass, MD, Lukas Heukamp, MB PhD, Roopika Menon, Miriam Bertrand, Claudia Wickenhauser, MD, Oana Brosteanu, PhD, Haifa Kathrin Al-Ali, MD

Blood (2019) 134 (Supplement_1): 1420.

https://doi.org/10.1182/blood-2019-127865

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Francesco Passamonti, MD, Lynda Foltz, MD FRCPC, David M Ross, MD PhD, Nicola Vianelli, MD, Alessandro M. Vannucchi, MD, Norio Komatsu, MD PhD, Pierre Zachée, Ranjan Tiwari, MSc, Evren Zor, MD, Shalini Chaturvedi, Geralyn Gilotti, MSc, Francisco Cervantes, MD

Blood (2019) 134 (Supplement_1): 2952.

https://doi.org/10.1182/blood-2019-124739

Published: 2019

Journal Articles

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Nadia Jaekel, MD, Karolin Hubert, Mathias Hänel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Susann Schulze, MD, Song-Yau Wang, MD, Christoph Kahl, MD, Maxi Wass, MD, Herbert G. Sayer, MD PhD, Oana Brosteanu, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali

Blood (2018) 132 (Supplement 1): 83.

https://doi.org/10.1182/blood-2018-99-115790

Published: 2018

Journal Articles

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)

Blood (2018) 132 (Supplement 1): 4292.

https://doi.org/10.1182/blood-2018-99-112377

Published: 2018

Journal Articles

Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

Haifa Kathrin Al-Ali, Lynda Foltz, Giuseppe A. Palumbo, Bruno Martino, Francesca Palandri, PhD MD, Anna Marina Liberati, Philipp Le Coutre, Carmen Garcia-Hernandez, Andrey Zaritskey, Renato Tavares, Martin Griesshammer, Vikas Gupta, MD PhD, Pia Raanani, Pilar Giraldo, PhD, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Francesco Mannelli, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 4204.

https://doi.org/10.1182/blood.V130.Suppl_1.4204.4204

Published: 2017

Journal Articles

Selection and Efficacy of Cytoreductive Agents in Patients with Mastocytosis Included in the Registry of the European Competence Network on Mastocytosis (ECNM)

Blood (2017) 130 (Supplement 1): 1650.

https://doi.org/10.1182/blood.V130.Suppl_1.1650.1650

Published: 2017

Journal Articles

Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

Thoralf Lange, MD, Rainer Krahl, PhD, Ulrich von Grünhagen, MD, Haifa Kathrin Al-Ali, Schwarzer Andreas, MD, Kathleen Jentsch-Ulrich, MD, Claudia Spohn, MD, Volker Lakner, MD, Michael Assmann, MD, Christian Junghanss, MD, Markus Pfirrmann, Arthur Gil, PhD, Rüdiger Hehlmann, MD, Michael W. Deininger, MD PhD, Dietger Niederwieser, MD

Blood (2017) 130 (Supplement 1): 1615.

https://doi.org/10.1182/blood.V130.Suppl_1.1615.1615

Published: 2017

NARROW

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Effect of New or Worsening Anemia on Clinical Outcomes in 2233 Patients with Myelofibrosis Treated with Ruxolitinib in the Expanded-Access Jump Study

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

The Incidence of Mastocytosis in Patients with Unclear Cytopenia and/or Leucocytosis: The Hryd Study

Phenotypes of JAK2 -Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)

Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

Selection and Efficacy of Cytoreductive Agents in Patients with Mastocytosis Included in the Registry of the European Competence Network on Mastocytosis (ECNM)

Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only